share_log

AbbVie | DEFA14A: Others

AbbVie | DEFA14A: Others

艾伯維公司 | DEFA14A:其他
美股sec公告 ·  03/18 16:22
Moomoo AI 已提取核心訊息
AbbVie Inc., a biopharmaceutical company, has filed a definitive additional materials proxy statement with the United States Securities and Exchange Commission (SEC). This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that AbbVie is preparing materials related to upcoming corporate matters that may require a vote by shareholders. The proxy statement is not preliminary and does not require a filing fee, suggesting that it is ready for review by shareholders and the SEC. The document is intended for use in connection with the company's forthcoming decisions and does not constitute soliciting material under §240.14a-12.
AbbVie Inc., a biopharmaceutical company, has filed a definitive additional materials proxy statement with the United States Securities and Exchange Commission (SEC). This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that AbbVie is preparing materials related to upcoming corporate matters that may require a vote by shareholders. The proxy statement is not preliminary and does not require a filing fee, suggesting that it is ready for review by shareholders and the SEC. The document is intended for use in connection with the company's forthcoming decisions and does not constitute soliciting material under §240.14a-12.
生物製藥公司艾伯維公司(AbbVie Inc.)已向美國證券交易委員會(SEC)提交了明確的附加材料委託書。根據1934年《證券交易法》第14(a)條提交的這份文件表明,艾伯維正在準備與即將發生的可能需要股東投票的公司事務有關的材料。委託書不是初步的,不需要申請費,這表明它已準備好供股東和美國證券交易委員會審查。該文件旨在與公司即將作出的決定相關使用,不構成第240.14a-12條規定的招標材料。
生物製藥公司艾伯維公司(AbbVie Inc.)已向美國證券交易委員會(SEC)提交了明確的附加材料委託書。根據1934年《證券交易法》第14(a)條提交的這份文件表明,艾伯維正在準備與即將發生的可能需要股東投票的公司事務有關的材料。委託書不是初步的,不需要申請費,這表明它已準備好供股東和美國證券交易委員會審查。該文件旨在與公司即將作出的決定相關使用,不構成第240.14a-12條規定的招標材料。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息